Successful CVOT 'Lights' Contrave 2nd chance path; Orexigen rises
This article was originally published in Scrip
Executive Summary
Contrave (naltrexone SR/bupropion SR) does not increase the risk of adverse cardiovascular (CV) events, according to much-anticipated interim study results from Orexigen Therapeutics, which handed investors the news they've been craving over the past year about the experimental anti-obesity drug.